生产企业：Corbus Pharmaceuticals
CRB-913 is an experimental, peripherally acting cannabinoid receptor 1 (CB1) inverse agonist developed by Corbus Pharmaceuticals for the treatment of obesity. It targets a cannabinoid receptor that regulates appetite, and in a Phase 1b trial it achieved about 5% weight loss; psychiatric side effects remain the key concern.
CRB-913 is an experimental, peripherally acting cannabinoid receptor 1 (CB1) inverse agonist developed by Corbus Pharmaceuticals for the treatment of obesity. It targets a cannabinoid receptor that regulates appetite, and in a Phase 1b trial it achieved about 5% weight loss; psychiatric side effects remain the key concern.
Peripherally restricted cannabinoid receptor 1 (CB1) inverse agonist
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
